The new oral drug for multiple sclerosis (MS), approved by the FDA, is Mayzent (siponimod) tablets.
Mayzent (Siponimod) for MS
The U.S. Food and Drug Administration approved Mayzent (siponimod) tablets on March 26, 2019, for treating adults with relapsing forms of multiple sclerosis (MS). This includes:
- Clinically isolated syndrome (CIS)
- Relapsing-remitting MS (RRMS)
- Active secondary progressive MS (SPMS)
Therefore, Mayzent (siponimod) is an oral medication used to treat various forms of relapsing MS.
